Biomarker testing is driving a new standard of care

Backed by leading cancer research and advocacy organizations, the Clear Your View initiative aims to ensure complete biomarker testing informs treatment decisions for every advanced cancer patient.

Use results to determine the best treatment plan

New targeted therapies are extending survival for patients with advanced cancers

Patients with targetable alterations respond better to targeted therapy than immunotherapy1

Incomplete testing can lead to sub-optimal patient outcomes

Targeted Therapy

50-83%

Response Rates

Immuno­therapy

4-26%

Response Rates

Overall Response, Targeted Therapy vs. Immunotherapy

60%

of CRC patients have a mutation that means anti-EGFRs will not work to treat their disease8

72% of advanced CRC patients who received anti-EGFR therapy did not have RAS and BRAF testing8

Roadmap to complete biomarker testing

STOP

Test every patient for all recommended biomarkers

WAIT

for complete biomarker results

TREAT

with the best possible therapies

Patients Are Asking

“What is stopping you from testing all of your lung cancer patients?”

“Do you have all the results before starting my first line treatment?”


Growing patient awareness

A thriving community of patient organizations advocate for complete testing before treatment

ALK Positive
Colontown\
Fight Colorectal Cancer
Global Colon Cancer Association
GO2 Foundation for Lung Cancer
KRAS Kickers
Lungevity
Paltown Development Foundation
Colorectal Cancer Alliance

Clear your view with our comprehensive reference kit